## Marco Peviani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2670752/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Selective Nanovector Mediated Treatment of Activated Proinflammatory Microglia/Macrophages in Spinal Cord Injury. ACS Nano, 2013, 7, 9881-9895.	14.6	136
2	Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation. Neurobiology of Disease, 2014, 62, 218-232.	4.4	110
3	Polymeric nanoparticle system to target activated microglia/macrophages in spinal cord injury. Journal of Controlled Release, 2014, 174, 15-26.	9.9	100
4	Multiple drug delivery hydrogel system for spinal cord injury repair strategies. Journal of Controlled Release, 2012, 159, 271-280.	9.9	84
5	Neuroprotective Effects of Toll-Like Receptor 4 Antagonism in Spinal Cord Cultures and in a Mouse Model of Motor Neuron Degeneration. Molecular Medicine, 2012, 18, 971-981.	4.4	66
6	Intracerebroventricular delivery of hematopoietic progenitors results in rapid and robust engraftment of microglia-like cells. Science Advances, 2017, 3, e1701211.	10.3	38
7	Biodegradable polymeric nanoparticles administered in the cerebrospinal fluid: Brain biodistribution, preferential internalization in microglia and implications for cell-selective drug release. Biomaterials, 2019, 209, 25-40.	11.4	37
8	Specific Induction of Akt3 in Spinal Cord Motor Neurons is Neuroprotective in a Mouse Model of Familial Amyotrophic Lateral Sclerosis. Molecular Neurobiology, 2014, 49, 136-148.	4.0	32
9	Toward the identification of neuroprotective agents: g-scale synthesis, pharmacokinetic evaluation and CNS distribution of ( <i>R</i> )-RC-33, a promising Sigma1 receptor agonist. Future Medicinal Chemistry, 2016, 8, 287-295.	2.3	30
10	Hydrazone linked doxorubicin-PLA prodrug nanoparticles with high drug loading. Nanotechnology, 2018, 29, 305602.	2.6	17
11	Heterogeneity of Neuroinflammatory Responses in Amyotrophic Lateral Sclerosis: A Challenge or an Opportunity?. International Journal of Molecular Sciences, 2020, 21, 7923.	4.1	15
12	Delivery Platforms for CRISPR/Cas9 Genome Editing of Glial Cells in the Central Nervous System. Frontiers in Genome Editing, 2021, 3, 644319.	5.2	11
13	Metallothioneins are neuroprotective agents in lysosomal storage disorders. Annals of Neurology, 2018, 83, 418-432.	5.3	10
14	A step forward in the sigma enigma: a role for chirality in the sigma1 receptor–ligand interaction?. MedChemComm, 2015, 6, 138-146.	3.4	9
15	Development of easyâ€toâ€use reverseâ€phase liquid chromatographic methods for determining PREâ€084, RCâ€33 and RCâ€34 in biological matrices. The first step for <i>in vivo</i> analysis of sigma1 receptor agonists. Biomedical Chromatography, 2016, 30, 645-651.	1.7	7
16	T1-Weighted Dynamic Contrast-Enhanced MRI Is a Noninvasive Marker of Epidermal Growth Factor Receptor vIII Status in Cancer Stem Cell–Derived Experimental Glioblastomas. American Journal of Neuroradiology, 2016, 37, E49-E51.	2.4	6
17	Bitopic Sigma 1 Receptor Modulators to Shed Light on Molecular Mechanisms Underpinning Ligand Binding and Receptor Oligomerization. Journal of Medicinal Chemistry, 2021, 64, 14997-15016.	6.4	6
18	Simultaneous Flow Cytometric Characterization of Multiple Cell Types Retrieved from Mouse Brain/Spinal Cord Through Different Homogenization Methods. Journal of Visualized Experiments, 2019, , .	0.3	4

#	Article	IF	CITATIONS
19	Lipophilic dye-compatible brain clearing technique allowing correlative magnetic resonance/high-resolution fluorescence imaging in rat models of glioblastoma. Scientific Reports, 2020, 10, 17974.	3.3	3
20	Synthesis and Characterization of a "Clickable―PBR28 TSPO-Selective Ligand Derivative Suitable for the Functionalization of Biodegradable Polymer Nanoparticles, Nanomaterials, 2021, 11, 1693	4.1	2

the Functionalization of Biodegradable Polymer Nanoparticles. Nanomaterials, 2021, 11, 1693. 20